Cryoport Express® Cryogenic HV3 Shipping System Expands Patient Access to Biologics and Other Temperature-Sensitive Life Saving Therapies
Newly Designed High-Volume Enclosure Showcased at Phacilitate’s Advanced Therapies Week 2025 in Dallas, TX
NASHVILLE, Tenn., February 3, 2025 – Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or “the Company”), a global leader in supply chain solutions for the life sciences, has announced the launch of its revolutionary Cryoport Express® Cryogenic HV3 Shipping System (“HV3”) from its subsidiary, Cryoport Systems. Designed to set a new standard in life science logistics, the HV3 ensures unmatched protection and accessibility for biologics and temperature-sensitive materials. The HV3 is the newest product innovation from Cryoport’s comprehensive global end-to-end temperature-controlled supply chain offerings and provides a streamlined solution to address compliance and risk mitigation challenges in the space and improve patient outcomes.
In response to evolving airline regulations for regional and commercial aircraft transport, Cryoport introduced the innovative design of the HV3 enclosure to minimize shipping delays for clients. The unique HV3 configuration eliminates the need for palletization on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. This enhancement opens up additional shipping lanes, making it easier for life-saving therapies to reach more remote destinations.
The HV3’s unique square enclosure provides optimized hold times for interior payloads, improved storage efficiency, and full compliance with airline requirements, all while preserving the viability of biological materials. Tailored to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security and superior temperature control, maintaining payload integrity and extended temperature stability at -150°C or lower.
Additionally, the HV3 features a redesigned structure that enhances mobility, improving accessibility at point-of-care sites. Designed with the end-user in mind, the HV3 features robust wheels and an integrated, front-facing handle to ensure easy mobility at any stage of transit. These streamlined improvements enable more efficient handling at care sites, contract development and manufacturing organizations (CDMOs), and storage facilities, reducing the need for additional site-based resources and boosting overall safety for operators.
“We are constantly working to anticipate industry challenges,” said Jerrell Shelton, CEO of Cryoport. “With the introduction of the Cryoport Express® Cryogenic HV3 Shipping System, we are expanding access to life-saving therapies in remote areas, ultimately improving patient outcomes.”
The Cryoport Express® Cryogenic HV3 Shipping System was showcased at Phacilitate’s Advanced Therapies Week, a key event focused on the development and commercialization of cell and gene therapies held in Dallas, TX, January 20-23, 2025. The HV3 was featured during two panel discussions on patient-centric advancements in the advanced therapies supply chain.
“The HV3 was a point of interest for attendees exploring solutions to the logistical challenges of transporting advanced therapies globally”, said Mike Dybicz, Chief Product Development Officer of Cryoport Systems. “We were privileged to be part of these speaking opportunities, united in our shared goal of enhancing patient access to life-saving therapies.”
Read the full press release for more details.